Latest Medical Devices News

Ansell Limited has announced a USD 0.222 per share dividend for the six months ending December 2024, payable in March 2025 with a full dividend reinvestment plan available.

Vitrafy Life Sciences reported a dramatic increase in half-year losses to $25.7 million, yet successfully raised $35 million through an IPO to fuel its cryopreservation technology expansion.

Micro-X Limited has requested an immediate voluntary suspension of its shares on the ASX, pending a forthcoming equity raising announcement expected by February 10.

OncoSil Medical has secured authorization for 120 German hospitals to negotiate funding for its pancreatic cancer treatment device, marking a 43% increase from last year and signaling growing acceptance in Germany’s healthcare system.

dorsaVi has secured a new commercial research project with renowned US surgeon Dr. Chirag Patel, leveraging its FDA-cleared wearable sensor technology and AI to enhance injury prevention and performance for elite athletes.

ResMed Inc. reported robust financial results for the quarter ended December 31, 2024, with a 10% increase in net revenue and a 65% jump in net income, driven by strong demand across its Sleep and Breathing Health and Residential Care Software segments.

Fisher & Paykel Healthcare anticipates increased costs from newly imposed US tariffs on imports from Mexico and China, potentially delaying its gross margin recovery timeline but expects no immediate profit impact for FY2025.

Argent BioPharma reports strategic cost-cutting moves including facility closures and delisting from the LSE, while securing German distribution approval and raising significant capital to support its drug pipeline.

Cadoux Limited reports significant progress in its high purity alumina and Minhub rare earths projects, alongside robust environmental, social, and governance initiatives.

Cardiex has kicked off deliveries of its CONNEQT Pulse arterial health monitors in the U.S., reporting strong preorder momentum and a 150% sales increase in December. The company’s strategic operational shifts and pharma partnerships set the stage for sustained growth in 2025.

Cardiex Limited reported a $2.94 million cash outflow for Q2 FY2025 but bolstered its balance sheet with a $3.25 million placement. The company has begun delivering its CONNEQT Pulse units, signaling a new revenue stream and ongoing R&D investment.

Nova Eye Medical Limited is raising A$6.6 million to strengthen its financial position following resolved supply chain disruptions, while reporting strong sales growth and nearing profitability in its glaucoma division.